About: The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1983

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1983 (uk) im Juli 1983 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1983 (ast) scientific article published on 01 July 1983 (en)
publication date	wds:Q71782599-025C591C-74E4-49AF-A354-E7C88917EFF5
publication date	1983-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71782599-1F0FAFFB-37DE-4A0E-A274-FFE830A0E331
language of work or name	English
author name string	wds:Q71782599-5571BCB3-1E6A-45A2-BC5D-B51BA85D3F80 wds:Q71782599-56CFA2DE-1A26-48E0-9FF5-F63CB8E69172 wds:Q71782599-5FF9B6A0-6141-4704-9380-AD72B80D3E1A wds:Q71782599-8C202E8F-FED6-460F-A8C9-088FEC1576A5 wds:Q71782599-A715C000-643C-4948-87CF-799ED84DB0E3 wds:Q71782599-F81F9E69-DDEC-4C46-A14C-5931D8B78F69
author name string	C V Leier D V Unverferth R D Magorien A J Kolibash R Altschuld R P Lewis
rdfs:label	The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (en) The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (nl)
skos:prefLabel	The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (en) The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (nl)
name	The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (en) The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (nl)
title	wds:Q71782599-5F922546-7C67-4B8F-A448-39D38D3E6E41
title	The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy (en)
page(s)	wds:Q71782599-52C07AC8-25F0-47D6-9436-E13D91209931
page(s)	29-34
instance of	wds:Q71782599-E313E96B-B1FC-4958-917D-1CBB123574A2
instance of	scholarly article
main subject	wds:Q71782599-89CF8524-612E-44D0-82AE-CD9D1F8FD2DB
main subject	cardiomyopathy
PubMed ID	wds:Q71782599-4E54AFEA-B6A7-42D3-8757-31B01D8055BC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/6869193
PubMed ID	6869193
published in	wds:Q71782599-2832A1C0-6C93-4ACF-AF13-C995CFDB9860
published in	American Heart Journal
issue	wds:Q71782599-52E7D067-02D5-4CA9-B4EE-15C4C4E3EEE8
volume	wds:Q71782599-D8E8CB4B-53C8-4971-A722-C14239C06230
issue	1 Pt 1
volume	106
DOI	wds:Q71782599-60F9ECA8-5135-4854-B74E-CD7D333C2E64
DOI	http://dx.doi.org/10.1016/0002-8703(83)90434-9
DOI	10.1016/0002-8703(83)90434-9
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71782599
is cites work of	Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions Prevention of bedrest-induced physical deconditioning by daily dobutamine infusions. Implications for drug-induced physical conditioning Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial Inotropes do not increase mortality in advanced heart failure A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list Is there a role for positive inotropic agents in congestive heart failure: focus on mortality Outpatient Dobutamine Therapy: The Rhyme and the Riddle Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure Current issues in advanced heart failure Inotropic therapy of the failing myocardium Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. Positive inotropic therapy: an update and new agents Intermittent dobutamine therapy in patients with advanced congestive heart failure Parenteral inotropic support for advanced congestive heart failure Myocardial energetics in dilated cardiomyopathy Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering? Local Dermal Hypersensitivity from Dobutamine Hydrochloride (Dobutrex Solution) Injection Effects of hypertonic saline solution on body weight and serum creatinine in patients with acute decompensated heart failure Effect of medical therapy on survival of patients with dilated cardiomyopathy Intravenous fenoldopam infusion in severe heart failure The unique management of refractory advanced systolic heart failure Chronotropic and inotropic responses to adrenoceptor agonists in vitro after chronic dobutamine treatment in the rabbit
is cites work of	wds:Q34561584-B2364D21-01C7-4F29-8DDF-AD20FA68BC2C wds:Q28293706-68961500-E08D-4144-BB28-975F3AC714EC wds:Q34687109-F5BBCAA7-96CA-4D3E-8E0D-8BA4F33467FA wds:Q68157608-C1BE1F7A-C0FA-4E04-ACC2-5192C199B506 wds:Q40867374-9DF41FE4-BBE3-406F-B0EF-6F6085FA67BC wds:Q36244456-28CF9546-6663-4A0C-AB57-9D50642DAAF8 wds:Q38951649-D646E940-60C6-43F7-ABEE-FA945060A96B wds:Q44251923-0951E825-300C-4DFC-80BB-F2B9A8508F37 wds:Q77746913-8951D1B3-8C7A-40E5-8285-8FD15088A001 wds:Q44829195-18004F00-D8B9-43B4-8FB1-463D116F669E wds:Q28327140-19286CC7-70B8-4B43-942C-F249A7EDB2E5 wds:Q33685748-D117B3C3-CEF3-482C-BA49-98E027C72730 wds:Q35350198-E4295A1A-D846-4A52-A6BA-9B5E364772A1 wds:Q33492163-37A40F8A-6C52-4B3D-ABAA-986DD3E230BA wds:Q71590582-2A1FCDF5-2452-4E2C-B8F6-BC509C214CF5 wds:Q73940048-C8416777-9AFE-42DD-A41B-25053CCABE94 wds:Q41563106-177AE387-930A-4090-A334-DB04105CE64C wds:Q44268627-6AD18AB4-8330-423B-8191-9861C3AE4185 wds:Q41608275-A0DF0CB6-6C7F-4E2B-880E-C6CD1EF5E710 wds:Q54319228-13C2A0D0-0595-4AAA-BD9F-FA7C26B11172 wds:Q53344976-477722C1-4CC7-4282-82F5-BCC85E3563A7 wds:Q36531828-19CB30D8-81D5-4353-95F4-49B65DE20403 wds:Q40599753-5C474385-2AAF-413E-9A4D-37AA194C7E55 wds:Q43823417-A4DFC0A3-34A3-41AA-99AE-B0D175C0DEF4

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software